Yaw Adjei-Poku, MD
Clinical Cardiac Electrophysiology · Albuquerque, NMNPI 1386872745
Payments from drug & device makers
Across 699 payments — averaging $2776.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1.4M
- Boehringer Ingelheim$367K
- Medtronic$53K
- Boehringer Ingelheim International GmbH$17K
- Biosense Webster, Inc.$15K
- Boston Scientific$11K
- plus $38K from 26 others
Across 4 payments — averaging $16,509 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$66K
What the payments were for
- Consulting fees$22,31343%
- Speaking & faculty fees$3,1256%
- Travel & lodging$12,15223%
- Food & beverage$14,50028%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 30 | $1,438,488 |
| Boehringer Ingelheim | 47 | $367,466 |
| Medtronic(2 entities) | 30 | $53,204 |
| Boehringer Ingelheim International GmbH | 110 | $16,931 |
| Biosense Webster, Inc. | 156 | $15,353 |
| Boston Scientific | 82 | $11,059 |
| ZOLL Respicardia, Inc. | 8 | $9,321 |
| Irhythm Technologies, Inc. | 6 | $8,071 |
| Medical Device Business Services, Inc. | 16 | $6,898 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $6,677 |
| Abbott | 134 | $4,078 |
| Stereotaxis Inc | 6 | $1,162 |
| E.r. Squibb & Sons, L.L.C. | 14 | $356 |
| Pfizer | 7 | $235 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $235 |
| Amgen | 11 | $156 |
| Atricure, Inc. | 1 | $151 |
| AstraZeneca | 4 | $132 |
| Bayer | 1 | $121 |
| Abiomed | 5 | $117 |
| Itamar Medical Inc | 2 | $110 |
| Johnson & Johnson(2 entities) | 5 | $87 |
| Novartis | 4 | $78 |
| Shockwave Medical, Inc | 4 | $58 |
| Chiesi USA, Inc. | 2 | $30 |
| Novo Nordisk | 1 | $28 |
| Philips North America LLC | 1 | $24 |
| Edwards Lifesciences | 1 | $23 |
| Medline Industries LP | 1 | $19 |
| Baxter Healthcare | 1 | $19 |
| Catheter Precision Inc. | 1 | $15 |
| Cardiva Medical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3$16,916
- ZIO XT Patch$8,002
- Farapulse$2,443
- Carto 3 System$2,391
- AVEIR$1,521
- Rhythmia Mapping System$903
- EMBLEM MRI S-ICD$783
- AMPLIA MRI QUAD CRT-D SURESCAN$760
- GENESIS$549
- Niobe$505
- Micra$249
- AZURE XT DR MRI SURESCAN$160
- Quadra Assura CRT Defibrillator$152
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$151
- ASSURITY$135
- WATCHMAN Access System$127
- Adempas$121
- Xience Sierra Coronary Stent$120
- ELIQUIS$119
- LifeVest$100
How this compares
Too few clinical cardiac electrophysiology providers in New Mexicoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 549 | $670,836 |
| XareltoRivaroxaban | 162 | $217,437 |
| EntrestoSacubitril/Valsartan | 37 | $43,261 |
| Dofetilide | 23 | $7,375 |
| Metoprolol Succinate | 302 | $6,788 |
| Flecainide Acetate | 137 | $4,901 |
| Mexiletine Hcl | 20 | $1,555 |
| Atorvastatin Calcium | 99 | $1,511 |
| Carvedilol | 116 | $1,127 |
| Diltiazem 24hr ErDiltiazem Hcl | 28 | $1,080 |
| Lisinopril | 111 | $847 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 41 | $819 |
| Potassium Chloride | 36 | $745 |
| Losartan Potassium | 76 | $739 |
| SotalolSotalol Hcl | 25 | $638 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $235 | $670,836549 claims |
| Johnson & JohnsonXarelto | $87 | $217,437162 claims |
| NovartisEntresto | $78 | $43,26137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical cardiac electrophysiology providers in New Mexicoon file to place this against a meaningful peer group, so we don't.
Other clinical cardiac electrophysiology in Albuquerque
- Michael HoskinsAlbuquerque$426K
- Sean MazerAlbuquerque$331K
- Michael BestawrosAlbuquerque$314K
- Daniel LevinAlbuquerque$44K
- Michael GardnerAlbuquerque$17K
- Luis ConstantinAlbuquerque$10K
- Sandeep NairAlbuquerque$6K
- Jerry ArellanoAlbuquerque$4K
- Shmuel InbarAlbuquerque$200
- Fernando TondatoAlbuquerque$39
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.